Recherche en France

Financement par le consortium REACTing

Dans le cadre du consortium REACTing, 20 projets ont été sélectionnés afin de mieux comprendre le virus, son épidémiologie et les moyens de le combattre. Le consortium a financé 20 projets de recherche dont 6 dans la catégorie "Diagnostic, recherche clinique et thérapeutique" :

  • Identification and characterization of human monoclonal antibodies neutralizing Covid-19 with the potential for development towards vaccine candidates. Hugo Mouquet (Inserm, Institut Pasteur)

  • Establishment of an antibody profile in convalescing patients and preparation of a serological test applied to an epidemiological survey in people exposed to SARS-Cov-2. Marc Eloit (Institut Pasteur : Pathogen Discovery laboratory)

  • Evolution of SARS-Cov-2 in the human host during infection and humoral response. Sylvie van der Werf (Institut Pasteur, CNRS - National Reference Center for Respiratory Viruses, Molecular Genetics of RNA Viruses)

  • Strategy of repurposing medicines to treat Covid-19 infections. Bruno Lina (Inserm, Université Claude Bernard Lyon 1, École Normale Supérieure, CNRS International Center for Research on Infectious Diseases – CIRI)

  • Implantation of an assisted ventilation protective mask: acceptability and incorporation in the organization of care. Jean-Christophe Lucet (Inserm, Université de Paris, Université Paris 13 Infection, Antimicrobials, Modelling, Evolution (IAME) unit)

  • Randomized, multicenter, adaptive study of the efficacy and safety of treatments for hospitalized patients presenting with Covid-19 infection. Florence Ader (Inserm, CNRS, Université Claude Bernard Lyon 1, École Normale Supérieure de Lyon - International Center for Research on Infectious Diseases (CIRI))

La recherche de vaccin